Primary outcome: incidence of renal relapseSecondary outcome:‘maintaining’ response (defined as complete or partial remission), changes of clinical parameters (including proteinuria, serum albumin, serum creatinine, eGFR and serum C3), and adverse effects (including leucopenia, infections, gastrointestinal complaints, liver function disorder and nephrotoxicity). This evidence concerns the gene ALB and infection.